Scinai Immunotherapeutics (SCNI) Non Operating Income (2014 - 2026)
Scinai Immunotherapeutics (SCNI) posted Non Operating Income of -$112000.0 for Q1 2026, up 70.68% sequentially from -$382000.0 in Q2 2025, and down 1118.18% YoY from $11000.0 in Q1 2025.
Scinai Immunotherapeutics (SCNI) Non Operating Income (2014 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Non Operating Income for 9 years, with the latest figure at -$112000.0 in Q1 2026.
- Quarterly Non Operating Income fell 1118.18% year-over-year to -$112000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 122.85% YoY) and the FY2025 annual result came in at -$1.2 million, up 8.23% from the prior year.
- Non Operating Income grew to -$112000.0 in Q1 2026 per SCNI's latest filing, from -$382000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $12.6 million in Q4 2022 and troughed at -$6.9 million in Q3 2022.
- A 4-year average of $691818.2 and a median of -$112000.0 in 2026 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2026: Non Operating Income surged 516.79% in 2023, then plunged 1118.18% in 2026.
- Over 4 years, Non Operating Income stood at $12.6 million in 2022, then sank by 45.19% to $6.9 million in 2023, then sank by 105.52% to -$382000.0 in 2025, then soared by 70.68% to -$112000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$112000.0, -$382000.0, and $11000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | -112,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112,000.00 |
| Jun 30, 2025 | -382,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2023 | 6.92 Mn |
| Sep 30, 2023 | -5.21 Mn |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | -329,000.00 |
| Dec 31, 2022 | 12.62 Mn |
| Sep 30, 2022 | -6.94 Mn |
| Jun 30, 2022 | -280,000.00 |
| Mar 31, 2022 | 140,000.00 |
| Mar 31, 2021 | -297,000.00 |
| Sep 30, 2019 | -260,000.00 |
| Jun 30, 2019 | -4.98 Mn |
| Mar 31, 2019 | -618,000.00 |
| Sep 30, 2018 | 992,000.00 |
| Dec 31, 2015 | 599,000.00 |
| Sep 30, 2015 | -2.35 Mn |
| Dec 31, 2014 | -206,000.00 |
| Sep 30, 2014 | -160,000.00 |